FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
Cabometyx found to reduce the risk of disease progression or death versus placebo in this patient population
Read More
Tag: thyroid cancer
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read More
NICE rejects thyroid cancer drugs
It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.
Read More
Eisai, NHS and NICE fail to reach deal on Lenvima
Patients with an advanced form thyroid cancer may have to wait three years for NHS access to Eiasai’s Lenvima in England, after the drug was left out of the newly launched Cancer Drugs Fund.
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
